Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-VEC with or without Pembrolizumab for Liver Tumors and Advanced Solid Tumors
NCT02509507Phase 2Completed
- Sponsor
- Amgen
- Start
- Feb 2016
- Primary completion
- Feb 2022
- Modality
- Oncolytic Viruses
- Countries
- 9
01
Overview
A Phase 2 trial of talimogene laherparepvec in hepatocellular carcinoma (HCC), breast cancer, colorectal cancer (CRC), gastroesophageal junction cancer, melanoma, sponsored by Amgen. Started Feb 2016; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
hepatocellular carcinoma (HCC)breast cancercolorectal cancer (CRC)gastroesophageal junction cancermelanoma
Beyond the preview
Go deeper on NCT02509507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02509507.